Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery
Authors:
- 28 January 2024
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 206, 115179
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (DK122638, DK126413)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK108736)
- Juvenile Diabetes Research Foundation United States of America
- JDRF (2-SRA-2021-1024-S-B, 3-SRA-2021-1033-S-B)
This publication has 225 references indexed in Scilit:
- Tacrolimus Inhibits the Revascularization of Isolated Pancreatic IsletsPLOS ONE, 2013
- Metabolic pathways in T cell fate and functionTrends in Immunology, 2012
- Polymeric Nanomaterials for Islet Targeting and Immunotherapeutic DeliveryNano Letters, 2011
- Advancing islet transplantation: from engraftment to the immune responseDiabetologia, 2011
- Natural killer cells in rejection and tolerance of solid organ allograftsCurrent Opinion in Organ Transplantation, 2011
- Human Induced Pluripotent Stem Cells Develop Teratoma More Efficiently and Faster Than Human Embryonic Stem Cells Regardless the Site of InjectionStem Cells, 2010
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends in Immunology, 2010
- The Many Roles of FAS Receptor Signaling in the Immune SystemImmunity, 2009
- Endothelial Cells in Allograft RejectionTransplantation, 2008
- Fas(CD95)/FasL interactions required for programmed cell death after T-cell activationNature, 1995